Search Results
Your search for ,dUe matches 5584 pages
Showing 201 - 250CMS Expects Between 750,000 to 2 Million to Lose Coverage If ACA Proposal Is Implemented
On March 10, 2025, the Centers for Medicare & Medicaid Services (CMS) released the Marketplace Integrity and Affordability Proposed Rule aimed at addressing improper enrollments in the Affordable Care Act (ACA) Health Insurance Marketplace. This is the first proposed rule released under the new ...
New Guideline Supports Transoral Robotic Surgery in the Multidisciplinary Management of Patients With Oropharyngeal Cancer
Transoral robotic surgery (TORS) can offer patients with oropharyngeal squamous cell carcinoma (OPSCC) improved survival while minimizing or avoiding late toxicities associated with the standard of care of radiation with cisplatin chemotherapy, according to a recent ASCO guideline.1 “We show in a...
Recent FDA Approvals in Lymphoma and in Rarer Tumors
The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris) in combination with lenalidomide and a rituximab product for adults with relapsed or refractory large B-cell lymphoma (LBCL)—including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising ...
Definitive Radiation Therapy Effectively Treats Locally Advanced BCC
Definitive radiation therapy offers a high degree of locoregional control in large, locally advanced basal cell carcinomas (BCC), according to results from a recent multi-institutional research study published by Su et al in the International Journal of Radiation Oncology · Biology · Physics. One...
Is Active Monitoring a Safe Option for Patients With Ductal Carcinoma In Situ?
With right-sizing treatment an aim of many treatment approaches in breast cancer today, ductal carcinoma in situ (DCIS), as well as its overtreatment, has become a potential target of change. Which patients, however, might safely forgo the current recommendations and be safely followed with active...
Do Congenital Heart Defects Affect Cancer Risk in Newborns and Their Mothers?
Newborns with congenital heart defects may have a higher risk of developing childhood cancer compared to children born without a heart abnormality. Further, congenital heart defects in newborns may also signal an elevated cancer risk for their mothers. These findings were published recently by Huh...
Moderate-to-Vigorous Physical Activity May Lower Risk of Cardiovascular Disease–Related Mortality in Women With a Cancer History
Taking more daily steps and engaging in moderate-to-vigorous physical activity may both be associated with a reduced risk of cardiovascular disease–related mortality among postmenopausal women with a history of cancer, according to preliminary findings presented by Hyde et al at the American Heart...
Cancer Incidence and Mortality in Southeast Asia for 2022
In a study reported in The Lancet Oncology, Dee et al identified cancer incidence and mortality rates for 2022 in the countries of southeast Asia. Study Details The study involved data from the GLOBOCAN 2022 database developed by the International Agency for Research on Cancer for the 11 countries...
Novel Antibody-Toxin Conjugate Evaluated in Early Study
Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors. According to preclinical results published in Nature Cancer, the new approach combined the benefits of antibody-drug...
Evaluation of Surrogate Endpoints for Overall Survival in Neoadjuvant Randomized Trials in Early Breast Cancer
In a study reported in Journal of Clinical Oncology, Conforti et al found that invasive disease–free survival with sufficient follow-up may be the best surrogate for overall survival in neoadjuvant randomized trials in early breast cancer. Study Details The study involved 11 trials with 15...
Pembrolizumab in Previously Treated Advanced Clear Cell Gynecological Cancers
As reported in JAMA Oncology by Kristeleit et al, the UK-based phase II PEACOCC trial has shown the benefit of pembrolizumab in previously treated patients with advanced clear cell gynecological cancers (CCGCs). As stated by the investigators, “Advanced CCGCs have a poor prognosis, with response...
Untreated CLL: Acalabrutinib Combinations vs Chemoimmunotherapy
As reported in The New England Journal of Medicine by Jennifer Brown, MD, and colleagues, the phase III AMPLIFY trial found that fixed-duration acalabrutinib combined with venetoclax or venetoclax/obinutuzumab improved progression-free survival vs chemoimmunotherapy in fit, previously untreated...
Talazoparib Plus Enzalutamide Significantly Improves Overall Survival in Prostate Cancer Regardless of HRR Gene Status
Studies show that about one-quarter of advanced prostate cancers have alterations in DNA damage response genes involved directly or indirectly in homologous recombination repair (HRR) gene alterations, including BRCA1/BRCA2 genes, which can sensitize them to treatment with PARP inhibitors. Final...
Only Half of Young Adults With Cancer Are Told of Fertility Preservation Options by Their Providers: Strategies for Improving That Number
Each year in the United States, approximately 90,000 adolescents and young adults (AYAs), defined as those between the ages of 15 and 39, are diagnosed with cancer, and about 9,300 die of the disease.1 Worldwide, the number of new cases of cancer in this age population tops 1,300,200—an increase of ...
FDA Approves Mirdametinib for Neurofibromatosis Type 1
On February 11, the U.S. Food and Drug Administration approved mirdametinib (Gomekli), a kinase inhibitor, for adult and pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. ReNeu Trial...
Is Thyroid Cancer Overdiagnosed?
A retrospective study provides new evidence that thyroid cancer continues to be overdiagnosed and that aggressive screening and treatment of thyroid cancer has not led to higher survival rates. The research was published by Chen et al in The Lancet Diabetes & Endocrinology. “Many studies have...
TACE and Durvalumab/Bevacizumab in Unresectable HCC
In the phase III EMERALD-1 trial reported in The Lancet, Sangro et al found that transarterial chemoembolization (TACE) with durvalumab/bevacizumab improved progression-free survival vs placebo in patients with unresectable hepatocellular carcinoma (HCC) amenable to embolization. Study Details In...
Tiragolumab Plus Atezolizumab/Bevacizumab in Unresectable, Locally Advanced, or Metastatic Hepatocellular Carcinoma
In a phase Ib-II study (MORPHEUS-Liver) reported in The Lancet Oncology, Finn et al found that the addition of tiragolumab, an anti-TIGIT monoclonal antibody, to atezolizumab/bevacizumab improved objective response rate in patients with unresectable, locally advanced, or metastatic hepatocellular...
Advanced NSCLC With Brain Metastases: Potential Novel Therapeutic Option
In a Chinese phase II study (C-Brain) reported in The Lancet Oncology, Xu et al found that brain radiotherapy in combination with camrelizumab and platinum-doublet chemotherapy produced “promising” results in patients with previously untreated advanced non–small cell lung cancer (NSCLC) with brain...
Addition of Lenvatinib/Pembrolizumab to TACE in Unresectable Nonmetastatic HCC
As reported in The Lancet by Kudo et al, the phase III LEAP-012 trial has shown a significant progression-free survival benefit with the addition of lenvatinib and pembrolizumab to transarterial chemoembolization (TACE) in patients with unresectable nonmetastatic hepatocellular carcinoma (HCC). A...
2.83% Medicare Physician Reimbursement Cut Finalized for 2025; Estimated 4% Cut for Medical Oncology
Late in 2024, the Centers for Medicare & Medicaid Services (CMS) issued the 2025 Physician Fee Schedule (PFS) final rule adopting changes for Medicare payments under the PFS. CMS also released the 2025 Hospital Outpatient Prospective Payment System final rule, which sets hospital outpatient...
AALL1731 Trial: Adding Blinatumomab to Standard Chemotherapy Improves Outcomes in Pediatric B-Cell ALL
Results of a phase III study suggest that the addition of the immunotherapy agent blinatumomab—a bispecific T-cell engager targeting CD19—to standard chemotherapy may help to prevent relapse in more children with B-cell acute lymphoblastic leukemia (B-ALL), the most common pediatric cancer,...
ACS Annual Report: Cancer Mortality Rates Decline, but Challenges Remain
The findings in the American Cancer Society’s annual report, Cancer Statistics, 2025, show a mixed trend in cancer incidence and mortality rates. While cancer mortality declined by 34% from 1991 to 2022 in the United States—largely due to smoking reductions, earlier detection, and improved...
New Research Approaches to Metastatic Breast Cancer
Tumor cells circulating in the blood are the germ cells of breast cancer metastases. They are rare and could not be propagated in the culture dish until now. A team from the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute HI-STEM, and the NCT Heidelberg has now succeeded...
Unresectable Locally Advanced KRAS-Mutant NSCLC
This is Part 3 of Clinical Perspectives on KRAS-Mutant NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Gregory Riely, Rebecca Heist, and Joshua Sabari discuss the management of a patient with unresectable locally...
Larotrectinib in Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors
In a Children’s Oncology Group study (ADVL1823) reported in Journal of Clinical Oncology, Laetsch et al found that larotrectinib was highly active in patients with newly diagnosed infantile fibrosarcoma and other pediatric NTRK fusion–positive solid tumors. Study Details The U.S. multicenter trial...
Primary Lung Tumor SBRT Followed by Concurrent Mediastinal Chemoradiotherapy and Immunotherapy Consolidation in Locally Advanced NSCLC
In a phase II trial reported in The Lancet Oncology, Heinzerling et al found evidence of efficacy of primary lung tumor stereotactic body radiotherapy (SBRT) followed by concurrent mediastinal chemotherapy and consolidative immunotherapy in patients with locally advanced non–small cell lung cancer...
Anthracyclines Plus Taxane-Based Chemotherapy for Certain Patients at High Risk for Breast Cancer Recurrence
Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2-negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline plus taxane-based chemotherapy regimens compared with those...
Nivolumab/Ipilimumab vs Chemotherapy With or Without Targeted Agents in MSI-H or dMMR Metastatic Colorectal Cancer
As reported in The New England Journal of Medicine by Andre et al, interim analysis of the phase III CheckMate 8HW trial has shown that nivolumab plus ipilimumab prolonged progression-free survival vs chemotherapy with or without targeted agents in patients with microsatellite instability–high...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Cameroon
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Cameroon. The aim of this special feature is to highlight the global cancer burden for various countries of the...
Understanding How Stigma and Incorrect Physician Assumptions About LGBTQ+ Patients’ Needs Contribute to Medical Mistrust
Over the past decade, ASCO has focused its resources on advancing health equity for sexual and gender minority (SGM) individuals with cancer. In 2017, the Society published a position statement “Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations,” which...
Impact of Prevention and Screening on Mortality From Five Common Cancers
Improvements in cancer prevention and screening have averted more deaths from five cancer types combined over the past 45 years than treatment advances, according to a modeling study led by researchers at the National Institutes of Health (NIH). The study, published by Goddard et al in JAMA...
Pediatric Cancer Clinical Trial Research Should Include Social Determinants of Health
ASCO is calling for pediatric clinical trials to prioritize health equity and social determinants of health (SDOH) data in future trials to improve cancer treatment and survivorship in patients. In a recent position statement, ASCO addresses the need to include SDOH data collection and intervention ...
The Future of Cancer Care, Part 2
The soaring number of cancer survivors since the National Cancer Act of 1971 was enacted into law provides a snapshot of the profound progress made against cancer over the past half-century: 3 million survivors in the 1970s,1 compared to more than 18 million today, and that number is expected to...
Understanding the Assessment and Treatment of High-Risk Myelofibrosis
At the 2024 JADPRO Live event, which is held annually for advanced practitioners in oncology, high-risk myelofibrosis was a featured topic. “The treatment landscape has developed so much that JADPRO asked us to present our talks on the main stage this year,” said Julie Huynh-Lu, PA-C, Supervisor...
Understanding the Link Between Obesity and Cancer
Worldwide, more than a billion people have obesity—including 650 million adults, 340 million adolescents, and 39 million children1—a rate that has nearly doubled since 1980.2 In the United States alone, about two out of three adults are overweight or have obesity, and one out of three have...
Adding Chemoradiation in Perioperative Gastric Cancer Treatment Improves Pathologic Response Rates Without Survival Benefit
Adding chemoradiation to perioperative chemotherapy improves pathologic complete response rates in patients with resectable gastric cancer but does not extend overall survival, according to data presented at the European Society for Medical Oncology (ESMO) Congress 20241 and published...
Daratumumab Induction Regimen in Transplant-Ineligible Patients Newly Diagnosed with Multiple Myeloma
In the phase III CEPHEUS trial,1 the achievement of undetectable measurable residual disease (or MRD negativity)—the primary endpoint—was met by 61% of patients with transplant-ineligible or deferred newly diagnosed multiple myeloma treated with the monoclonal antibody daratumumab plus bortezomib, ...
MRD-Guided Chemotherapy Intensification After Induction in Fit Older Patients With AML
As reported in the Journal of Clinical Oncology by Russell et al, the NCRI AML18 trial has shown survival benefit with treatment intensification in fit older patients with measurable residual disease (MRD)-positive response after first induction for acute myeloid leukemia (AML). Study Details In...
Radiotherapy With Durvalumab or Cetuximab in Locoregionally Advanced Head and Neck Cancer With Contraindication for Cisplatin
As reported in The Lancet Oncology by Mell et al, the phase II/III NRG-HN004 trial of radiotherapy with durvalumab or cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma and contraindications for cisplatin was stopped for futility during phase II; the phase III...
Effect of Myeloma Therapy in a Patient With Monoclonal Gammopathy of Thrombotic Significance
In a letter to the editor in The New England Journal of Medicine, Salmasi et al described identification of monoclonal gammopathy of thrombotic significance (MGTS) in a patient with coronary artery disease and its successful treatment with daratumumab, bortezomib, and dexamethasone (DVd). As...
PEACE-3: Enzalutamide Plus Radium-223 Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer
Initial analysis from the PEACE-3 trial suggests that the addition of radium-223 dichloride to enzalutamide could offer a promising new first-line treatment option for patients with metastatic castration-resistant prostate cancer, according to data presented by lead study author, Silke Gillessen,...
ADRIATIC Trial: Durvalumab Consolidation Extends Survival in Limited-Stage Small Cell Lung Cancer
Consolidation therapy with the PD-1 immune checkpoint inhibitor durvalumab is set to become the new global standard of care for patients with limited-stage small cell lung cancer (SCLC), according to groundbreaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024.1...
Highlights From the ESMO Congress 2024
The European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona featured several groundbreaking trials with the potential to significantly influence clinical practice. These studies highlighted the benefits of new combination immunotherapy strategies and innovative approaches in the...
Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer
The studies summarized below were reported online over the past month in The ASCO Post, generating a high number of visitors. For comprehensive reviews of these studies and more, visit ASCOPost.com. Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer In the phase...
Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?
Question: Based on NATALEE and monarchE data, is there still a need for neoadjuvant chemotherapy in hormone receptor (HR)-positive, HER2-negative early breast cancer? Answer: In monarchE trial, the CDK4/6 inhibitor abemaciclib combined with endocrine therapy demonstrated long-term efficacy in...
Increase in Young-Onset Pancreatic Cancer May Be Due to Overdiagnosis of Early-Stage Endocrine Cancer
A recent analysis of pancreatic cancer data in young adults (aged 15–39) has found that although there is an increase in incidence, the mortality rate remains stable. According to Patel et al, who published their findings in the Annals of Internal Medicine, the rise in incidence is primarily due to ...
In Case You Missed It: Roundup From ESMO Congress 2024
In addition to our in-depth analysis of important clinical trials presented at the European Society for Medical Oncology (ESMO) Congress 2024, there is always room for more coverage from The ASCO Post, including these brief summaries of other presentations of interest. They focus on a potential...
Medical-Legal Partnerships: A Promising Innovation in Oncology
Beyond the physical toll of the disease and its treatments, cancer often presents a host of legal and social issues that can significantly worsen a patient’s well-being and treatment outcomes. This column explains how medical-legal partnerships can offer a powerful tool to address these challenges ...
Neoadjuvant Therapy Yields Notable Outcomes in Triple-Negative Breast Cancer
The studies summarized below were reported online over the past month in The ASCO Post, generating a high number of visitors. For comprehensive news of these studies and more, visit ASCOPost.com. Triple-Negative Breast Cancer: Phase III KEYNOTE-522 The phase III KEYNOTE-522 trial has...
